Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Genge

Showing results (101-110 of 111) with videos related to

Pageof 12
Sort By:
JAMA Neurology|March 24, 2025
Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical TrialJeremy M Shefner, Merit E Cudkowicz, Angela Genge, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 12, 2025
Hospitalizations as an outcome measure in COURAGE-ALSStacy A Rudnicki, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 31, 2023
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of successJeremy M Shefner, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Plos One|December 4, 2025
Comprehensive analysis platform to understand, remedy, and eliminate amyotrophic lateral sclerosis (CAPTURE ALS): Study protocol for a Canadian multicenter, multimodal, longitudinal observational studyNatalie Saunders, Claire Magnussen, HyungMo Kang, et al.
The Lancet. Neurology|May 23, 2024
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichael Benatar, Thomas Hansen, Dror Rom, et al.
The Lancet. Neurology|April 17, 2024
Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trialRabi Tawil, Kathryn R Wagner, Johanna I Hamel, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 28, 2022
Primary lateral sclerosis natural history study - planning, designing, and early enrollmentHiroshi Mitsumoto, Grace Jang, Ikjae Lee, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|June 5, 2020
A National Spinal Muscular Atrophy Registry for Real-World EvidenceVictoria L Hodgkinson, Maryam Oskoui, Joshua Lounsberry, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 11, 2020
The NEALS primary lateral sclerosis registrySabrina Paganoni, Fabiola De Marchi, James Chan, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 24, 2020
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of <i>Reldesemtiv</i> In Patients With ALSJeremy M Shefner, Jinsy A Andrews, Angela Genge, et al.
Pageof 12

Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
JAMA Neurology|March 24, 2025
Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical TrialJeremy M Shefner, Merit E Cudkowicz, Angela Genge, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 12, 2025
Hospitalizations as an outcome measure in COURAGE-ALSStacy A Rudnicki, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 31, 2023
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of successJeremy M Shefner, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Plos One|December 4, 2025
Comprehensive analysis platform to understand, remedy, and eliminate amyotrophic lateral sclerosis (CAPTURE ALS): Study protocol for a Canadian multicenter, multimodal, longitudinal observational studyNatalie Saunders, Claire Magnussen, HyungMo Kang, et al.
The Lancet. Neurology|May 23, 2024
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichael Benatar, Thomas Hansen, Dror Rom, et al.
The Lancet. Neurology|April 17, 2024
Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trialRabi Tawil, Kathryn R Wagner, Johanna I Hamel, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 28, 2022
Primary lateral sclerosis natural history study - planning, designing, and early enrollmentHiroshi Mitsumoto, Grace Jang, Ikjae Lee, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|June 5, 2020
A National Spinal Muscular Atrophy Registry for Real-World EvidenceVictoria L Hodgkinson, Maryam Oskoui, Joshua Lounsberry, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 11, 2020
The NEALS primary lateral sclerosis registrySabrina Paganoni, Fabiola De Marchi, James Chan, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 24, 2020
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of <i>Reldesemtiv</i> In Patients With ALSJeremy M Shefner, Jinsy A Andrews, Angela Genge, et al.
Pageof 12